🩸 Additional insights on myeloma biology and microenvironment

#MultipleMyeloma #EquilibriumPhase #Immunotherapy #HEMEHUB #EscapePhase #PD1 #CTLA4 #BCells #HemeOnc #Hematology

New open-access study reveals two distinct ways anti-CTLA-4 therapy can boost anti-tumour immunity, and highlights the surprising role of soluble CTLA-4 as both a challenge and a potential therapeutic tool.

🔗 https://bit.ly/4k6jcZj

#Immunotherapy #CTLA4 #CancerResearch

High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis - Communications Medicine Røssevold et al. identify a subset of patients with early-stage basal-like breast cancer with an excellent prognosis, defined by high tumor expression of the immune checkpoint gene CTLA4. These patients are currently considered high-risk and receive extensive systemic treatment, which the authors suggest could safely be de-escalated or omitted.

🚨 NEW RESEARCH! ⚕️ 🩺

Røssevold et al. find that basal-like breast cancer patients with high levels of the immune-related gene CTLA4 in tumor had less recurrence after initial treatment and excellent prognoses.

https://bit.ly/45R95DZ #BreastCancer #CTLA4

Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity CTLA-4 exists as membrane (mCTLA-4) and soluble (sCTLA-4) forms. Immunological roles of sCTLA-4 are scarcely known. With mice deficient in either sCTLA-4 or mCTLA-4, Osaki et al. show that sCTLA-4, wh...

www.cell.com/immunity/abs...

#Treg #CTLA4

🚨 Immunology: sCTLA-4 prevents excessive Th1-driven inflammation, while mCTLA-4 suppresses Th2 responses.

Sakaguchi and et al.

Only two authors on this paper? 🤔 Bet the acknowledgments section is working overtime 🤫

#Immunology
#CTLA4
#Tregs

#cancer #tumour #immunity #ctla4 #tregs #immunecheckpointblockade… | John Gordon #Cancer | #Tumour #Immunity | #CTLA4: "A Tale of Two Pathways" | Breaking OPEN ACCESS Review Online from Frank Ward & Co. | BOTH #Tregs-Depletion AND…

#Immunotherapy Advances

#CTLA4: two pathways to anti- #tumour #immunity?

Breaking Open Access Review @imtadvances.bsky.social @britsocimm.bsky.social

Prof Hussein Tawbi #melanoma #Immunotherapy guru @mdanderson.bsky.social talks evolution of first line therapy. Highlights #LAG3 & lays out summary of what may be optimal for first line therapy & what looks promising/ #PD1 #CTLA4 #nivo #Ipi @bmsnews.bsky.social
#BRIDGE2024 @sitcancer.bsky.social

#checkpointinhibitors #PD1 #CTLA4 #NKcells #PersonalizedMedicine #PrecisionMedicine #ImmunoOncology #CancerTherapy #mRNATherapy #RegenerativeMedicine #Crispr #Bcell

#PD1 #CTLA4 #NKcells #PersonalizedMedicine #PrecisionMedicine #ImmunoOncology #CancerTherapy #mRNATherapy #RegenerativeMedicine #Crispr #Bcell

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T ... CD19-directed CAR T cell therapy is an effective treatment for B cell malignancies, but some patients fail to respond. Agarwal et al. demonstrate that deletion of CTLA4 enhances anti-tumor efficacy ...

The effects of the CTLA4 deletion were not very surprising, what's fascinating here is how it compares to the double mutants (PD1/CTLA4).

#Immunology #Immunotherapy #CheckpointInhibitor #CTLA4 #CARTcells

Check out http://cri-iatlas.org for our new modules with genomics data and interactive visualizations for 6 studies on the molecular response to #CTLA4 and #PD1/#PDL1 checkpoint inhibitors! #immunoOncology #cancerGenomics #immunology #systemsBiology 1/2